文献速递免疫规划卫生政策与健康促进

5-11岁儿童二价COVID-19 mRNA疫苗加强针安全性监测——美国,2022年10月12日至2023年1月1日

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-01-13

CDC审查了5-11岁儿童接种二价mRNA加强针后v-safe和VAERS报告的不良事件。v-safe登记儿童中局部反应68.7%、全身反应49.5%;VAERS报告中约99.8%为非严重事件,无心肌炎或死亡报告。局部和全身反应与单价加强针一致,严重不良事件罕见。

要点

  • 5-11岁儿童接种二价加强针后局部反应68.7%、全身反应49.5%。
  • VAERS报告中约99.8%为非严重事件,无心肌炎或死亡报告。
  • 局部和全身反应与单价加强针一致,严重不良事件罕见。

核心结论

  • 5-11岁儿童接种二价mRNA加强针后局部和全身反应与单价加强针一致,严重不良事件罕见。
  • 5-11岁儿童二价加强针接种前11周的初步安全性结果令人安心。

研究设计与样本

  • CDC审查了2022年10月12日至2023年1月1日期间5-11岁儿童接种二价Pfizer-BioNTech和Moderna加强针后向v-safe和VAERS报告的不良事件和健康影响。
  • 期间共861251名5-11岁儿童接种二价Pfizer-BioNTech加强针,92108名6-11岁儿童接种二价Moderna加强针。
  • v-safe登记了3259名接种二价加强针的5-11岁儿童。

主要发现

  • v-safe登记的3259名5-11岁儿童中,接种后一周内局部反应报告率为68.7%,全身反应报告率为49.5%。
  • VAERS收到的5-11岁儿童二价加强针接种后报告中约99.8%为非严重事件。
  • 二价加强针接种后无心肌炎或死亡报告。
  • 84%的VAERS报告与接种错误相关,其中90.5%未列出不良健康事件。

关键数值与推荐

  • FDA于2022年10月12日发布紧急使用授权,允许5-11岁儿童(Pfizer-BioNTech)和6-17岁儿童(Moderna)在完成基础免疫或单价加强针接种≥2个月后接种单剂二价mRNA COVID-19疫苗。
  • 2022年12月8日FDA修订紧急使用授权,纳入≥6月龄儿童。
  • ACIP建议所有≥6月龄人群在完成COVID-19基础免疫或接种单价加强针≥2个月后接种年龄适宜的二价mRNA加强针。

临床怎么用

  • 疫苗接种提供者在向父母或监护人咨询二价加强针接种时应提供上述信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On October 12, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for bivalent (mRNA encoding the spike protein from the SARS-CoV-2 ancestral strain and BA.4/BA.5 Omicron variants) formulations of Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines for use as a single booster dose ≥2 months after completion of primary series or monovalent booster vaccination for children aged 5-11 years (Pfizer-BioNTech) and 6-17 years (Moderna); on December 8, 2022, FDA amended the EUAs to include children aged ≥6 months (1,2). The Advisory Committee on Immunization Practices (ACIP) recommends that all persons aged ≥6 months receive an age-appropriate bivalent mRNA booster dose (3). The safety of bivalent mRNA booster doses among persons aged ≥12 years has previously been described (4). To characterize the safety of bivalent mRNA booster doses among children aged 5-11 years after receipt of bivalent Pfizer-BioNTech and Moderna booster doses, CDC reviewed adverse events and health impacts reported to v-safe,* a voluntary, smartphone-based U.S. safety surveillance system established by CDC to monitor adverse events after COVID-19 vaccination, and to the Vaccine Adverse Event Reporting System (VAERS), a U.S. passive vaccine safety surveillance system co-managed by CDC and FDA† (5). During October 12-January 1, 2023, a total of 861,251 children aged 5-11 years received a bivalent Pfizer-BioNTech booster, and 92,108 children aged 6-11 years received a bivalent Moderna booster.§ Among 3,259 children aged 5-11 years registered in v-safe who received a bivalent booster dose, local (68.7%) and systemic reactions (49.5%) were commonly reported in the week after vaccination. Approximately 99.8% of reports to VAERS for children aged 5-11 years after bivalent booster vaccination were nonserious. There were no reports of myocarditis or death after bivalent booster vaccination. Eighty-four percent of VAERS reports were related to vaccination errors, 90.5% of which did not list an adverse health event. Local and systemic reactions reported after receipt of a bivalent booster dose are consistent with those reported after a monovalent booster dose; serious adverse events are rare. Vaccine providers should provide this information when counseling parents or guardians about bivalent booster vaccination. Preliminary safety findings from the first 11 weeks of bivalent booster vaccination among children aged 5-11 years are reassuring. Compared with the low risk of serious health effects after mRNA COVID-19 vaccination, the health effects of SARS-CoV-2 infection include death and serious long-term sequalae (6). ACIP recommends that all persons aged ≥6 months receive an age-appropriate bivalent mRNA booster dose ≥2 months after completion of a COVID-19 primary series or receipt of a monovalent booster dose.¶.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Hause AM, Marquez P, Zhang B, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36634021. doi:10.15585/mmwr.mm7202a5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。